verified SJR 1,957 · Q1 • database Scopus / SJR & Web of Science & DOAJ indexed

Netherlands · John Wiley and Sons Ltd

workspace_premium Q1 — Medicine (miscellaneous) verified Plan S Compliant visibility_off Single blind Peer Review lock_open Open Access · DOAJ

Molecular Oncology

Molecular Oncology is a journal indexed in SJR in Medicine (miscellaneous) and Genetics with an H index of 121. It is an CC BY Journal with a Single blind Peer Review review system, and It has a price of 2700 €. The scope of the journal is focused on cancer, molecular biology, molecular genetics. It has an SJR impact factor of 1,957 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,957.

Molecular Oncology focuses its scope in these topics and keywords: cancer, gene, lymphoma, carcinoma, breast, negatively, ovarian, pathway, hormonenaive, activity, ...

ISSN: 1574-7891

Publisher: John Wiley and Sons Ltd

Category: Medicine (miscellaneous)

Indexation: verifiedScopus / SJR verifiedWeb of Science verifiedDOAJ

open_in_new Portal NPD menu_book Author guidelines

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,957 Q1

H-index 121

Acceptance rate pie_chart

25% Selective

Source Acceptance_Rate

Time to publication hourglass_top

10 weeks

Field Average_time_publication_weeks

Publication cost (APC) payments

2.700 € Open Access

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science DOAJ

SJR Impact

1,957

H-index

121

Docs (year)

218

Docs 3y

628

Total refs

15365

Cites 3y

3418

Citable 3y

604

Cites/Doc 2y

4.51

Ref/Doc

70.48

Immediate OA

2700 €

Embargoed OA

NPD

Non OA / Submission

- €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Corrigendum to "Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I-III" [Mol. Oncol. 8 (2) (2014) 417-30]

ZNF281/Zfp281 is a target of miR-1 and counteracts muscle differentiation

ERBB3 is required for tumor promotion in a mouse model of skin carcinogenesis

Enhanced expression of retinoic acid receptor alpha (RARA) induces epithelial-to-mesenchymal transition and disruption of mammary acinar structures

Endothelin-converting enzyme-1c promotes stem cell traits and aggressiveness in colorectal cancer cells

Endoplasmic reticulum stress and cell death in mTORC1-overactive cells is induced by nelfinavir and enhanced by chloroquine

EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: Inhibition by resveratrol

Editorial

Ebselen abrogates TNFa induced pro-inflammatory response in glioblastoma

Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cells

Development of an anti-BAG3 humanized antibody for treatment of pancreatic cancer

Defective postreplication repair of UV photoproducts in melanoma: a mutator phenotype

SHOW MORE ARTICLES

Deciphering tissue-based proteome signatures revealed novel subtyping and prognostic markers for thymic epithelial tumors

4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer

Comparative analysis of TTF-1 binding DNA regions in small-cell lung cancer and non-small-cell lung cancer

Citral reduces breast tumor growth by inhibiting the cancer stem cell marker ALDH1A3

Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer

Circ-TCF4.85 silencing inhibits cancer progression through microRNA-486-5p-targeted inhibition of

Chromatin and the DNA damage response: The cancer connection

Bringing in health technology assessment and cost-effectiveness considerations at an early stage of drug development

Biomarkers in oncology drug development

Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer

Benchmarking biology research organizations using a new, dedicated tool

BCG-induced cytokine release in bladder cancer cells is regulated by Ca

FAQs

Molecular Oncology has an SJR of 1,957 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is 2700 EUR.

The acceptance rate recorded for Molecular Oncology is 25%.

Molecular Oncology

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Molecular Oncology?

What is the APC / publication cost?

What is the acceptance rate?